Treating hyperlipidemia in African Americans

L. Michael Prisant, Carl Thurmond, Vincent Jb Robinson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The purpose of this paper is to provide information concerning the treatment of hyperlipidemia in African Americans. There is a similar prevalence of hypercholesterolemia in Blacks and Whites, but Blacks have been neglected in most pharmacological studies of hyperlipidemia. Intimal atherosclerotic involvement of the aorta and coronary artery occurs in young Black and White males. Epidemiological studies suggest there is a higher mortality rate due to coronary disease in Blacks vs Whites in the United States. Thirty-four percent of Blacks require a fasting lipid profile and 9% of Black adults aged 20 years or older would require lipid-lowering therapy. However, fewer Blacks (26%) than Whites (47%) are aware of their hypercholesterolemia. Studies with lovastatin and pravastatin show efficacy in the treatment of hypercholesterolemia. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is designed to determine all-cause mortality for subjects receiving pravastatin vs a control group receiving "usual care." Randomized, blinded, prospective trials are needed to assess the impact of hyperlipidemia as a risk factor, and the impact of its reduction in African Americans.

Original languageEnglish (US)
Pages (from-to)334-342
Number of pages9
JournalEthnicity and Disease
Volume10
Issue number3
StatePublished - Sep 1 2000

Fingerprint

Hyperlipidemias
African Americans
Hypercholesterolemia
Pravastatin
Lipids
Tunica Intima
Lovastatin
Mortality
Antihypertensive Agents
Coronary Disease
Aorta
Epidemiologic Studies
Fasting
Coronary Vessels
Therapeutics
Myocardial Infarction
Pharmacology
Control Groups
hydroquinone

Keywords

  • African American
  • Hyperlipidemia

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health

Cite this

Prisant, L. M., Thurmond, C., & Robinson, V. J. (2000). Treating hyperlipidemia in African Americans. Ethnicity and Disease, 10(3), 334-342.

Treating hyperlipidemia in African Americans. / Prisant, L. Michael; Thurmond, Carl; Robinson, Vincent Jb.

In: Ethnicity and Disease, Vol. 10, No. 3, 01.09.2000, p. 334-342.

Research output: Contribution to journalArticle

Prisant, LM, Thurmond, C & Robinson, VJ 2000, 'Treating hyperlipidemia in African Americans', Ethnicity and Disease, vol. 10, no. 3, pp. 334-342.
Prisant LM, Thurmond C, Robinson VJ. Treating hyperlipidemia in African Americans. Ethnicity and Disease. 2000 Sep 1;10(3):334-342.
Prisant, L. Michael ; Thurmond, Carl ; Robinson, Vincent Jb. / Treating hyperlipidemia in African Americans. In: Ethnicity and Disease. 2000 ; Vol. 10, No. 3. pp. 334-342.
@article{de0abf7bc71e46588bed6749db9cba57,
title = "Treating hyperlipidemia in African Americans",
abstract = "The purpose of this paper is to provide information concerning the treatment of hyperlipidemia in African Americans. There is a similar prevalence of hypercholesterolemia in Blacks and Whites, but Blacks have been neglected in most pharmacological studies of hyperlipidemia. Intimal atherosclerotic involvement of the aorta and coronary artery occurs in young Black and White males. Epidemiological studies suggest there is a higher mortality rate due to coronary disease in Blacks vs Whites in the United States. Thirty-four percent of Blacks require a fasting lipid profile and 9{\%} of Black adults aged 20 years or older would require lipid-lowering therapy. However, fewer Blacks (26{\%}) than Whites (47{\%}) are aware of their hypercholesterolemia. Studies with lovastatin and pravastatin show efficacy in the treatment of hypercholesterolemia. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is designed to determine all-cause mortality for subjects receiving pravastatin vs a control group receiving {"}usual care.{"} Randomized, blinded, prospective trials are needed to assess the impact of hyperlipidemia as a risk factor, and the impact of its reduction in African Americans.",
keywords = "African American, Hyperlipidemia",
author = "Prisant, {L. Michael} and Carl Thurmond and Robinson, {Vincent Jb}",
year = "2000",
month = "9",
day = "1",
language = "English (US)",
volume = "10",
pages = "334--342",
journal = "Ethnicity and Disease",
issn = "1049-510X",
publisher = "ISHIB",
number = "3",

}

TY - JOUR

T1 - Treating hyperlipidemia in African Americans

AU - Prisant, L. Michael

AU - Thurmond, Carl

AU - Robinson, Vincent Jb

PY - 2000/9/1

Y1 - 2000/9/1

N2 - The purpose of this paper is to provide information concerning the treatment of hyperlipidemia in African Americans. There is a similar prevalence of hypercholesterolemia in Blacks and Whites, but Blacks have been neglected in most pharmacological studies of hyperlipidemia. Intimal atherosclerotic involvement of the aorta and coronary artery occurs in young Black and White males. Epidemiological studies suggest there is a higher mortality rate due to coronary disease in Blacks vs Whites in the United States. Thirty-four percent of Blacks require a fasting lipid profile and 9% of Black adults aged 20 years or older would require lipid-lowering therapy. However, fewer Blacks (26%) than Whites (47%) are aware of their hypercholesterolemia. Studies with lovastatin and pravastatin show efficacy in the treatment of hypercholesterolemia. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is designed to determine all-cause mortality for subjects receiving pravastatin vs a control group receiving "usual care." Randomized, blinded, prospective trials are needed to assess the impact of hyperlipidemia as a risk factor, and the impact of its reduction in African Americans.

AB - The purpose of this paper is to provide information concerning the treatment of hyperlipidemia in African Americans. There is a similar prevalence of hypercholesterolemia in Blacks and Whites, but Blacks have been neglected in most pharmacological studies of hyperlipidemia. Intimal atherosclerotic involvement of the aorta and coronary artery occurs in young Black and White males. Epidemiological studies suggest there is a higher mortality rate due to coronary disease in Blacks vs Whites in the United States. Thirty-four percent of Blacks require a fasting lipid profile and 9% of Black adults aged 20 years or older would require lipid-lowering therapy. However, fewer Blacks (26%) than Whites (47%) are aware of their hypercholesterolemia. Studies with lovastatin and pravastatin show efficacy in the treatment of hypercholesterolemia. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is designed to determine all-cause mortality for subjects receiving pravastatin vs a control group receiving "usual care." Randomized, blinded, prospective trials are needed to assess the impact of hyperlipidemia as a risk factor, and the impact of its reduction in African Americans.

KW - African American

KW - Hyperlipidemia

UR - http://www.scopus.com/inward/record.url?scp=0034280657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034280657&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 334

EP - 342

JO - Ethnicity and Disease

JF - Ethnicity and Disease

SN - 1049-510X

IS - 3

ER -